Why the study?
Does colchicine therapy reduce in-stent restenosis, repeat PCI, and mortality in a real-world cohort of DES recipients?
Cohort
Does colchicine therapy reduce in-stent restenosis, repeat PCI, and mortality in a real-world cohort of DES recipients?
Answers are grounded in this paper and cite their sources.
In a real-world cohort of DES recipients, colchicine therapy was associated with reduced risks of in-stent restenosis, repeat PCI, and all-cause mortality without increasing bleeding risk.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pitaro et al. (2026) conducted a cohort in Drug-eluting stent (DES) recipients. Colchicine vs. Standard care / No colchicine was evaluated on In-stent restenosis (ISR) (HR 0.84, 95% CI 0.77-0.92, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: